Recently, CD8+/PD-1+ T cells have been implicated in the reduced sensitivity to PD-1 inhibition in animal models of HCC secondary to non-viral aetiology, further highlighting the adverse role of these T cell subset in driving disease progression and response to therapy.34 Here, CD8A is linked to hepatocellular carcinoma.